OptimizeRx Sales Momentum Continues with Two New Enterprise-level Engagements Added to its Digital Health Platform
2020年7月7日 - 9:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, has secured
two new SaaS-based enterprise-level engagements that provide the
full spectrum of access to the company’s nationwide digital
healthcare platform.
One win represents a new platform client and the other the
transition of a legacy client to the company’s new enterprise
solution suite. The two deals have on average an annual contract
value of $3.6 million.
“These wins demonstrate the exceptional capabilities and reach
of our solutions and their proven ability to deliver value to our
clients,” said OptimizeRx chief commercial officer, Steve
Silvestro. “Our enterprise engagements have been producing strong
results due to the improved interoperability between our
point-of-care and direct-to-patient solutions, with this all
working together to deliver better outcomes for patients.
“As pharma continues to see restricted travel and limited
patient access to healthcare providers due to COVID-19, our
platform has become a ‘must-have’ solution for maintaining the flow
of critical communications between industry and healthcare
providers regardless of location.”
OptimizeRx’s newly integrated digital health platform enables
unprecedented transparency into patient medication behavior, and
provides access to patient-provider-pharma communications across
the care continuum and in a variety of care settings. By improving
these communications, pharmaceutical companies, healthcare
providers and payers can more efficiently and effectively address
patient medication affordability and therapeutic adherence.
OptimizeRx CEO, William Febbo, commented: “We are encouraged
by the continued conversion of our pipeline of enterprise-level
opportunities and the resulting buildup in recurring revenue. As
these more expansive enterprise deployments better address the need
for greater digital connectivity, they also provide us more revenue
per customer and a more consistent revenue stream.”
“Our up-sell opportunity for converting just our legacy clients
from individual solutions to enterprise platform engagements
remains greater than $100 million,” added Febbo. “While naturally
this will not be realized overnight, these two wins, making it six
in total so far in 2020, demonstrate the strength of our new sales
team and solid results from our integrated platform approach.”
About OptimizeRxOptimizeRx Corporation (NASDAQ:
OPRX) is a digital health company that facilitates communication at
point-of-care among all stakeholders in healthcare. Primarily
focused on life science and payer clients, its suite of digital and
mobile SaaS-based solutions enables affordability, patient
adherence and care management. OptimizeRx’s network reaches more
than 60% of U.S. ambulatory providers, delivering therapeutic
support on specialty medications and patient financial assistance
directly within a provider’s workflow through leading electronic
health platforms. OptimizeRx’s fully integrated platform supports
the real-time exchange of information, improving provider knowledge
and patient engagement, and ultimately leading to healthier
outcomes.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel (248)
651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira Alejandra, Media
Relations ManagerTel (754) 245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both, CMATel
(949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024